Trial Profile
A 24-week, Dose-ranging, Multicenter, Double-blind, Double-dummy, Active-controlled Core Study to Evaluate Canakinumab for Prophylaxis of Signs and Symptoms of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy and a 24-week Open-label, Multicenter Extension Study to Assess Safety, Tolerability and Efficacy of Canakinumab in Patients With Gout Who Are Given Canakinumab at the Time of Gout Flare
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Allopurinol; Colchicine
- Indications Gout
- Focus Therapeutic Use
- Acronyms H2251
- Sponsors Novartis
- 21 Jun 2010 New trial record
- 18 Jun 2010 Preliminary results were presented at EULAR 2010, according to a Novartis media release.